Bausch & Lomb's Crystalens approved by FDA
This article was originally published in Clinica
Executive Summary
Bausch & Lomb's Crystalens HD accommodating intraocular lens (IOL) has received premarket approval (PMA) from the US FDA. It is the fourth-generation Crystalens product – the first gained FDA clearance in November 2003. The Rochester, New York company hopes to launch the lens in Europe, Asia and Canada in early 2009. Bausch & Lomb agreed to buy Crystalens' developer eyeonics in January 2008 – before this it only offered monofocal IOLs. Crystalens is designed to correct presbyopia, the eye's inability to accommodate and focus on close objects, using the eye muscles to push the IOL back and forth. Crystalens HD has an enhanced optic which increases depth of focus to improve near vision without compromising intermediate or distance vision, Bausch & Lomb said.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.